|
|
||||||||
J Thorac Cardiovasc Surg 2005;129:569-575
© 2005 The American Association for Thoracic Surgery
Surgery for Congenital Heart Disease |
a Department of Pediatric Cardiology and Pediatric Intensive Care Medicine, Tuebingen University Hospital and Hannover Medical School
b Department of Thoracic, Cardiac and Vascular Surgery, Tuebingen University Hospital, Tuebingen, Germany
Received for publication February 26, 2004; revisions received August 11, 2004; accepted for publication August 20, 2004. * Address for reprints: Renate Kaulitz, MD, Department of Pediatric Cardiology and Pediatric Intensive Care Medicine, Tuebingen University Hospital, Hoppe-Seyler Str 3, D-72076, Tuebingen, Germany (E-mail: renate.kaulitz{at}med.uni-tuebingen.de).
| Abstract |
|---|
|
|
|---|
METHODS: We evaluated 142 surviving patients after total cavopulmonary anastomosis (mean follow-up was 91.1 ± 43.9 months). Prophylactic antithrombotic treatment was initiated in 86 patients with partial prosthetic venous pathway with acetylsalicylic acid; 45 patients with complete autologous tissue venous pathway or partial prosthetic venous pathway received no anticoagulation, and 11 patients received warfarin sodium (Coumadin). During long-term follow-up, 22 patients (12 after acetylsalicylic acid medication) crossed over to warfarin.
RESULTS: Thrombotic events occurred in 10 patients (7%), with systemic venous thrombus formation in 8 (5.6%), stroke in 2 (1.4%), and a peak incidence during the first postoperative year. Eight of 10 patients were receiving heparin therapy mainly for prolonged postoperative immobilization. During follow-up, none of the 74 patients receiving acetylsalicylic acid and 1 of 40 patients without medication presented with thrombus formation. Under warfarin medication, 1 of 28 patients had an asymptomatic thrombus. Expected freedom from a thromboembolic event was 92% at 5 years and 79% at 10 years. There was no association with coagulation factor abnormalities. Protein-losing enteropathy was present in 4 of 10 patients.
CONCLUSION: A prophylactic anticoagulation strategy that considers the surgical technique and potential predisposing circumstances proved effective in the prevention of late thrombotic complications after total cavopulmonary anastomosis. There is no need for routine anticoagulation during long-term follow-up after Fontan-type surgery in pediatric patients.
The optimum type and duration of postoperative anticoagulation therapy is still a matter of discussion because no controlled studies comparing different strategies preventing thromboembolic complications are available yet. Initial anticoagulation with warfarin sodium (Coumadin) has been recommended by some authors for all patients after Fontan-type surgery irrespective of the individual situation.5,12,13
In this study we analyzed the initial intention to treat and assessed the results of a long-term risk-stratified prophylactic treatment depending on the potential predisposing circumstances in our patients after a total cavopulmonary anastomosis.
| Patients and methods |
|---|
|
|
|---|
|
The initial antithrombotic treatment was based on the surgical method and influenced by preoperative parameters and early postoperative functional result. It was modified during long-term follow-up when thromboembolic complications occurred or sequelae such as atrial tachydysrhythmia, symptomatic protein-losing enteropathy, polycythemia, or ventricular dysfunction associated with systemic venous slow blood flow phenomenon on echocardiogram developed. This resulted in 22 cross-overs to warfarin during follow-up.
After the early postoperative period, 85 patients with a partial prosthetic venous pathway (including patients with tunnel fenestration) were treated with acetylsalicylic acid (ASA; 3-5 mg/kg per day). No anticoagulation was administered to 16 patients with autologous tissue venous pathways and 29 patients with partial prosthetic venous pathways and an uncomplicated early postoperative period. Six patients received warfarin as initial treatment because of borderline preoperative hemodynamic parameters or related to surgical technique. Eight patients received heparin for prolonged pleural effusions or immobilization and crossed over to ASA or warfarin during follow-up (Figure 1).
|
| Statistical analysis |
|---|
|
|
|---|
| Results |
|---|
|
|
|---|
|
|
The number of patients who received warfarin increased from 6 to 28 during follow-up. Cross-over to warfarin was initiated because of a thromboembolic event in 7 patients or the development of potential predisposing causes for thromboembolic complications (Table 3); prophylactic anticoagulation was begun 16 to 110 months (mean 56.2 ± 32.2 months) postoperatively. None of these patients had bleeding complications. Patients without any antithrombotic prophylaxis had significantly longer mean follow-up (123.8 ± 32.3 months) compared with patients who received warfarin (101.4 ± 46.6 months; P = .04) or ASA (69.7 ± 34.8 months; P= .005).
|
| Discussion |
|---|
|
|
|---|
Anticoagulation strategies have been considered with various ideas concerning the indication and type and duration of therapy.8,13,16 Some of these suggestions, however, were based on the experience of patients undergoing previous types of univentricular palliation. These included a high proportion of patients with atriopulmonary anastomosis or total cavopulmonary anastomosis and a blind pouch left after main pulmonary artery ligation/division. Because of a high incidence of late thromboembolic complications in these patients, long-term anticoagulant therapy with warfarin was recommended for all patients undergoing a Fontan procedure irrespective of the surgical technique or additional predisposing factors.9,13 On the basis of the assumption that potential risk factors may exist and can be used as a rationale to decide on different anticoagulation treatment regimens, we assessed the relationship between individualized treatment and outcome, that is, thromboembolic problems in patients after total cavopulmonary anastomosis. Our results show that the surgical technique is relevant in 2 aspects. None of the 16 patients with an autologous tunnel procedure had thrombus formation, although they did not receive any anticoagulation medication as part of our strategy. This may be related to the nonturbulent systemic venous flow dynamics with the preservation of a somewhat pulsatile flow by atrial contraction and less respiratory-dependent venous return.19 Thrombus formation in the residual pulmonary trunk after pulmonary artery ligation or division with the risk of arterial embolization and cerebral infarction is not a rare event; it has been described in approximately 30% to 50% of patients with thrombus formation after univentricular palliation.9,18 However, it was our policy to start to close any pulmonary trunk at the pulmonary valve annulus level. We succeeded in all but 1 patient, who was then administered anticoagulation treatment. Because of the potentially serious sequelae, diagnosis of a thrombus in the pulmonary stump should prompt urgent removal and closure of the pulmonary valve even in asymptomatic patients.16
As reported in the literature, the type of material used for creation of the lateral tunnel or the presence of fenestrations did not affect the risk of stroke.7,17,18 After tunnel fenestration, a high proportion of spontaneous fenestration closures during follow-up has been described, limiting the potential risk of paradoxic thromboembolism.20 In our study, patients with persistent tunnel fenestration were placed on ASA (except for 2 patients), although an increased risk of stroke has not been proven in these patients.7
Early experience in patients who underwent an extracardiac conduit procedure revealed a high incidence of thrombus formation,5,21 but the number of patients under extended follow-up is still limited. None of the young patients who had recently undergone an extracardiac conduit procedure at our institution were placed on warfarin. However, we never used prosthetic tubes in the extracardiac Fontan procedure; we used as much autologous tissue (mainly in situ pericardium) as possible.
All patients with a history of thrombus formation in our study had at least 1 potential predisposing factor that might increase the risk of thromboembolic complications. The findings of other investigators4,7,22 (ie, supraventricular tachycardia and IART may promote thrombus formation on an atrial level) prompted us to anticoagulate our patients with recurrent atrial tachydysrhythmia. Thrombus formation in association with the diagnosis of protein-losing enteropathy occurred in 4 of our 10 patients. This clinical observation had not been made in the literature. The potential risk of imbalance of the procoagulant and anticoagulant factors in patients with protein-losing enteropathy, resulting from similar molecular weights for albumin, protein C and S, antithrombin III, and factors II and X, had already been described by Cromme-Dijkhuis and associates.10 Patients with protein-losing enteropathy and thrombus formation in our study did not show a uniform pattern of coagulation factor abnormalities. Under therapy with warfarin, none of these patients experienced further thrombosis during follow-up.
The follow-up in our patients was too short and the number of patients was too small to confirm the impression of other studies that the incidence of arrhythmias and thromboembolic events increases with the duration of follow-up, especially after 10 years.2,13 On the other hand, patients with long-term follow-up and adult patients are at risk for systemic ventricular dysfunction; in this case, we believe that anticoagulation treatment is indicated especially when contrast echocardiograms demonstrate a slow blood flow situation, which is probably caused by spontaneous microcavitations within the cavopulmonary connection.23 One major potential predisposing factor in our study was prolonged postoperative immobilization documented in 4 patients with thrombus formation. Postoperative heparinization was routinely started in all patients shortly after the Fontan procedure or noncardiac surgery (with prolongation of partial thromboplastin time to 50-60 seconds), as recommended in adults and adapted for children.6 However, disease states might coexist that influence plasma concentrations of antithrombin or the anticoagulant capacity of heparin by an increase in acute phase proteins.6,8 Coagulation factor abnormalities potentially predisposing to thromboembolic events have been described in recent reports in various constellations after the Fontan procedure, suggesting an unpredictable risk of imbalance in procoagulant and anticoagulant factors with the need for anticoagulation treatment.24,25 However, there is presently no coagulation profile that can be used to identify patients at increased risk for thrombus formation or permanent abnormal consumption of coagulation factors.
Limitations of the study
Transesophageal echocardiography has proven to be the method of choice to identify intracardiac thrombi in the majority of asymptomatic patients, especially older children and young adults.5,9,23 Because transesophageal echocardiography was not performed on a routine basis in all of our patients, the true incidence of asymptomatic cardiac thrombi may have been underestimated.
The relatively small number of patients with a thromboembolic event during follow-up limits the possibility of identifying a risk factor with statistical significance.
| Conclusion |
|---|
|
|
|---|
| See related editorial on page 491.
|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. Khairy and N. Poirier Is the Extracardiac Conduit the Preferred Fontan Approach for Patients With Univentricular Hearts?: The Extracardiac Conduit Is Not the Preferred Fontan Approach for Patients With Univentricular Hearts Circulation, November 20, 2012; 126(21): 2516 - 2525. [Full Text] [PDF] |
||||
![]() |
T. M. Giglia, J. DiNardo, N. S. Ghanayem, R. Ichord, R. A. Niebler, K. C. Odegard, M. P. Massicotte, A. R. Yates, P. C. Laussen, and J. S. Tweddell Bleeding and Thrombotic Emergencies in Pediatric Cardiac Intensive Care: Unchecked Balances World Journal for Pediatric and Congenital Heart Surgery, October 1, 2012; 3(4): 470 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Makhija and R. Sharma Hematologic Alterations in Patients with Functionally Univentricular Hearts World Journal for Pediatric and Congenital Heart Surgery, July 1, 2012; 3(3): 350 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sakurai, H. Kado, T. Nakano, K. Hinokiyama, S. Oda, J. Sugiura, T. Ushijima, and Y. Ueda The impact of extracardiac conduit-total cavopulmonary connection on apicocaval juxtaposition Eur J Cardiothorac Surg, October 1, 2010; 38(4): 439 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sathanandam, A. C. Polimenakos, C. Blair, C. El Zein, and M. N. Ilbawi Hypoplastic Left Heart Syndrome: Feasibility Study for Patients Undergoing Completion Fontan at or Prior to Two Years of Age Ann. Thorac. Surg., September 1, 2010; 90(3): 821 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Robbers-Visser, M. Miedema, A. Nijveld, E. Boersma, A. J. J. C. Bogers, F. Haas, W. A. Helbing, and L. Kapusta Results of staged total cavopulmonary connection for functionally univentricular hearts; comparison of intra-atrial lateral tunnel and extracardiac conduit Eur J Cardiothorac Surg, April 1, 2010; 37(4): 934 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sreeram, M. Emmel, U. Trieschmann, M. Kruessell, K. Brockmeier, L. B. Mime, and G. Bennink Reopening acutely occluded cavopulmonary connections in infants and children Interact CardioVasc Thorac Surg, March 1, 2010; 10(3): 383 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Karsies, K. K. Nicol, M. E. Galantowicz, J. A. Stephens, and B. A. Kerlin Thrombotic Risk of Recombinant Factor Seven in Pediatric Cardiac Surgery: A Single Institution Experience Ann. Thorac. Surg., February 1, 2010; 89(2): 570 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Odegard, D. Zurakowski, J. A. DiNardo, R. A. Castro, F. X. McGowan Jr., E. J. Neufeld, and P. C. Laussen Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 934 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Kim, W.-H. Kim, H.-G. Lim, and J.-Y. Lee Outcome of 200 patients after an extracardiac Fontan procedure J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 108 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Khairy, S. M. Fernandes, J. E. Mayer Jr, J. K. Triedman, E. P. Walsh, J. E. Lock, and M. J. Landzberg Long-Term Survival, Modes of Death, and Predictors of Mortality in Patients With Fontan Surgery Circulation, January 1, 2008; 117(1): 85 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakano, H. Kado, T. Tachibana, K. Hinokiyama, A. Shiose, M. Kajimoto, and Y. Ando Excellent Midterm Outcome of Extracardiac Conduit Total Cavopulmonary Connection: Results of 126 Cases Ann. Thorac. Surg., November 1, 2007; 84(5): 1619 - 1626. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Khairy, N. Poirier, and L.-A. Mercier Univentricular Heart Circulation, February 13, 2007; 115(6): 800 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ono, D. Boethig, H. Goerler, M. Lange, M. Westhoff-Bleck, and T. Breymann Clinical outcome of patients 20 years after Fontan operation -- effect of fenestration on late morbidity Eur J Cardiothorac Surg, December 1, 2006; 30(6): 923 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Petrossian, V. M. Reddy, K. K. Collins, C. B. Culbertson, M. J. MacDonald, J. J. Lamberti, O. Reinhartz, R. D. Mainwaring, P. D. Francis, S. P. Malhotra, et al. The extracardiac conduit Fontan operation using minimal approach extracorporeal circulation: early and midterm outcomes. J. Thorac. Cardiovasc. Surg., November 1, 2006; 132(5): 1054 - 1063. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |